JP2012126695A - Estrogen-like active agent and skin preparation for external use - Google Patents
Estrogen-like active agent and skin preparation for external use Download PDFInfo
- Publication number
- JP2012126695A JP2012126695A JP2010281748A JP2010281748A JP2012126695A JP 2012126695 A JP2012126695 A JP 2012126695A JP 2010281748 A JP2010281748 A JP 2010281748A JP 2010281748 A JP2010281748 A JP 2010281748A JP 2012126695 A JP2012126695 A JP 2012126695A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- extract
- estrogen
- eucalyptus
- leaf extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 230000001076 estrogenic effect Effects 0.000 title abstract description 23
- 239000013543 active substance Substances 0.000 title abstract 3
- 239000000284 extract Substances 0.000 claims abstract description 81
- 244000166124 Eucalyptus globulus Species 0.000 claims abstract description 41
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 33
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 33
- 235000004692 Eucalyptus globulus Nutrition 0.000 claims abstract description 5
- 239000000262 estrogen Substances 0.000 claims description 13
- 230000000699 topical effect Effects 0.000 claims description 6
- 229940051257 eucalyptus globulus leaf extract Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 34
- 230000037303 wrinkles Effects 0.000 abstract description 7
- 230000002500 effect on skin Effects 0.000 abstract description 5
- 206010040849 Skin fissures Diseases 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 77
- 235000003392 Curcuma domestica Nutrition 0.000 description 28
- 235000013976 turmeric Nutrition 0.000 description 28
- 239000002904 solvent Substances 0.000 description 17
- 230000006872 improvement Effects 0.000 description 16
- 239000006210 lotion Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 229960005309 estradiol Drugs 0.000 description 7
- 229930182833 estradiol Natural products 0.000 description 7
- 230000037330 wrinkle prevention Effects 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010049290 Feminisation acquired Diseases 0.000 description 1
- 208000034793 Feminization Diseases 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- -1 pack Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、エストロゲン様作用剤およびそれを含有する皮膚外用剤に関する。本発明の皮膚外用剤は、肌荒れ改善効果、シワ防止・改善効果、美肌効果に優れ、かつ肌へのなじみが良く、使用後のべたつきが無い等の使用感にも優れるとともに経時安定性にも優れている。 The present invention relates to an estrogenic agent and an external preparation for skin containing the same. The skin external preparation of the present invention is excellent in rough skin improvement effect, wrinkle prevention / improvement effect, beautifying skin effect, is well-familiar to the skin, has excellent feeling of use such as no stickiness after use, and is stable over time Are better.
エストロゲンは、卵胞ホルモンまたは女性ホルモンとも呼ばれ、発情ホルモンに特有な生物学的作用をもつ天然物質あるいは合成物質の総称を表わす用語として用いられている。一般には、エストロン、エストラジオール、エストリオールが知られており、特にエストラジオールは哺乳類に普通にみられる卵胞ホルモンのうち最も有効なものであり、卵巣、胎盤、睾丸、副腎皮質などで生成される。 Estrogens are also called follicular hormones or female hormones, and are used as a general term for natural substances or synthetic substances having a biological action peculiar to estrus hormones. In general, estrone, estradiol, and estriol are known. In particular, estradiol is the most effective follicular hormone commonly found in mammals and is produced in the ovary, placenta, testis, adrenal cortex, and the like.
エストロゲンは、ステロイドホルモンの一種であり、その受容体を介して生理作用を示し、その受容体は生殖器や乳腺のみならず全身の細胞に存在し、その働きは多岐に渡っている。エストロゲンの作用については、一般的には、乳腺細胞の増殖促進、卵巣***制御、脂質代謝制御、インスリン作用、血液凝固作用、中枢神経（意識）女性化、ＬＤＬ（low density lipoprotein）の減少とＶＬＤＬ（very low density lipoprotein）・ＨＤＬ（high density lipoprotein）の増加による動脈硬化抑制などが知られている。 Estrogen is a kind of steroid hormone and exhibits physiological action through its receptor. The receptor is present not only in genital organs and mammary glands but also in cells of the whole body, and its functions are diverse. Regarding the action of estrogen, in general, promotion of breast cell proliferation, ovarian ovulation control, lipid metabolism control, insulin action, blood coagulation action, central nervous (conscious) feminization, LDL (low density lipoprotein) decrease and VLDL Arteriosclerosis suppression by an increase in (very low density lipoprotein) and HDL (high density lipoprotein) is known.
皮膚においては、エストラジオールの投与によって皮膚中のヒアルロン酸含量が増加するにつれて皮膚水分量も増加するという報告（非特許文献１）、エストラジオールの欠乏により真皮中のゼラチナーゼが増加し皮膚の弾力性が低下するという報告（非特許文献２）、エストラジオール軟膏の大規模臨床試験から閉経後の女性の紫外線老化皮膚に対してエストラジオールが有効であったという報告（非特許文献３）がなされている。 In the skin, reports that estradiol administration increases the moisture content of the skin as the hyaluronic acid content in the skin increases (Non-patent Document 1). Due to the lack of estradiol, gelatinase in the dermis increases and skin elasticity decreases. According to a large-scale clinical trial of estradiol ointment, non-patent document 3 reports that estradiol was effective against postmenopausal women's UV-aged skin (non-patent document 3).
しかしながら、エストロゲン投与によるホルモン療法には、副作用があることからその投与の調整が非常に難しいという問題、また医師の管理化で行わなければならないという問題があった。 However, hormonal therapy by estrogen administration has problems that it is very difficult to adjust the administration due to side effects, and that it must be performed under the control of a doctor.
そこで近年、特許文献１，２に開示されているように、エストロゲン様作用を有する植物の抽出物を用いて女性ホルモンバランスを調整することにより、皮膚などの老化防止を試みる提案がなされている。しかしながら、これら特許文献に記載の抽出物においても安定して十分な効果を得られるものが無いのが現状であり、また、老化防止と肌質改善を実感するのは困難であった。 Therefore, in recent years, as disclosed in Patent Documents 1 and 2, proposals have been made to try to prevent the aging of skin and the like by adjusting the female hormone balance using a plant extract having an estrogen-like action. However, in the present situation, none of the extracts described in these patent documents can stably obtain a sufficient effect, and it has been difficult to realize aging prevention and skin quality improvement.
また、エストロゲン様作用を有する植物の抽出物を含有する皮膚外用剤には、肌へのなじみが悪かったり、使用後にべたつきがあるなど、使用感に劣るものがあり、また経時安定性に劣るものもあった。 In addition, some external preparations containing an extract of a plant having an estrogen-like action have poor usability, such as poor skin fit and stickiness after use, and poor stability over time. There was also.
本発明の目的は、従来のものに比べ高活性なエストロゲン様作用剤を提供すること、また、肌荒れ改善効果、シワ防止・改善効果、美肌効果に優れ、かつ肌へのなじみが良く、使用後のべたつきが無い等の使用感にも優れるとともに、経時安定性にも優れている皮膚外用剤を提供することである。 The purpose of the present invention is to provide a highly active estrogen-like agent compared to the conventional ones, and also has an effect of improving rough skin, an effect of preventing and improving wrinkles, an effect of beautifying skin, and is well-familiar to the skin. It is to provide an external preparation for skin which is excellent in feeling of use such as no stickiness and has excellent temporal stability.
本発明者らは、上記課題を解決するために、様々な植物抽出物についてエストロゲン様作用を調べた結果、ユーカリ葉抽出物がエストロゲン様作用を有すること、さらに、ユーカリ葉抽出物にウコン根茎抽出物を組み合わせることで、ユーカリ葉抽出物単独に比べてエストロゲン様作用が飛躍的に増大することを見出した。また、ユーカリ葉抽出物を含有する皮膚外用剤、あるいは、ユーカリ葉抽出物とウコン根茎抽出物を含有させた皮膚外用剤は、肌荒れ改善効果、シワ防止・改善効果、美肌効果に優れ、かつ肌へのなじみが良く、使用後のべたつきが無い等の使用感にも優れるとともに、経時安定性にも優れていることを見出し、本発明を完成させるに至った。 In order to solve the above-mentioned problems, the present inventors have examined estrogen-like action for various plant extracts. As a result, the eucalyptus leaf extract has an estrogen-like action. It was found that the estrogen-like effect was dramatically increased by combining the eucalyptus leaves as compared with the eucalyptus leaf extract alone. In addition, a skin external preparation containing a eucalyptus leaf extract, or a skin external preparation containing a eucalyptus leaf extract and a turmeric rhizome extract has an excellent effect on improving rough skin, preventing wrinkles, improving skin, and improving the skin. The present invention was completed by finding out that it is well-familiar with, excellent in feeling of use such as no stickiness after use, and excellent in stability over time.
すなわち本発明は、ユーカリ（Eucalyptus globulus）葉抽出物からなるエストロゲン様作用剤、ユーカリ（Eucalyptus globulus）葉抽出物とウコン（Curcuma longa）根茎抽出物からなるエストロゲン様作用剤、およびこれらの抽出物を含有する皮膚外用剤である。 That is, the present invention relates to an estrogenic agent composed of Eucalyptus globulus leaf extract, an estrogenic agent composed of Eucalyptus globulus leaf extract and turmeric (Curcuma longa) rhizome extract, and extracts thereof. Contains a topical skin preparation.
なお、ユーカリ葉抽出物については、これまでにセラミド産生促進剤（特許文献３）、皮膚バリアー機能改善剤（特許文献４）等が知られているが、ユーカリ葉抽出物がエストロゲン様作用を有することは未だ報告されていない。また、ウコン根茎抽出物については、発酵させたウコンの抽出物がエストロゲン様作用を有することが報告されているが（特許文献５）、その作用効果は十分であるとはいえない。 As for eucalyptus leaf extract, ceramide production promoter (Patent Document 3), skin barrier function improving agent (Patent Document 4) and the like have been known so far. Eucalyptus leaf extract has an estrogenic action. This has not been reported yet. Moreover, about the turmeric rhizome extract, although the fermented turmeric extract has been reported to have an estrogen-like action (Patent Document 5), it cannot be said that the action effect is sufficient.
本発明のエストロゲン様作用剤は、従来のエストロゲン様作用剤に比べ高活性なエストロゲン様作用を有する。また、本発明の皮膚外用剤は、肌荒れ改善効果、シワ防止・改善効果、美肌効果に優れ、かつ肌へのなじみが良く、使用後のべたつきが無い等の使用感にも優れるとともに、経時安定性にも優れるものである。 The estrogen-like agent of the present invention has a highly active estrogen-like effect as compared with conventional estrogen-like agents. In addition, the external preparation for skin of the present invention is excellent in rough skin improvement effect, wrinkle prevention / improvement effect, beautifying skin effect, is well-familiar to the skin, has excellent feeling of use such as no stickiness after use, and is stable over time. It is also excellent in properties.
以下、本発明の実施形態について説明する。本発明のエストロゲン様作用剤および皮膚外用剤は、いずれもユーカリ葉抽出物を含有し、好ましくは更にウコン根茎抽出物を含有する。本発明で用いられるユーカリ葉抽出物およびウコン根茎抽出物について説明する。 Hereinafter, embodiments of the present invention will be described. Each of the estrogenic agent and the external preparation for skin of the present invention contains a eucalyptus leaf extract, and preferably further contains a turmeric rhizome extract. The eucalyptus leaf extract and turmeric rhizome extract used in the present invention will be described.
〔ユーカリ葉抽出物〕
本発明に用いられるユーカリは、フトモモ科ユーカリノキ属に属する植物であり、学名はEucalyptus globulusと呼ばれている。オーストラリアの南東端部とタスマニア島に分布し、耐寒性があり生長が早いので世界各地で造林用に用いられている。地中海沿岸で多く栽植され、日本には明治初めに栽植された。樹高は４５〜５５ｍ、直径は１. ２〜２ｍになる常緑高木である。樹皮は灰色で、薄片状に細長くはげ、青灰色のはげ跡が残る。葉は著しい異型性を示し、若木では長さ約１０ｃｍの卵形、無柄で対生し、成木では長さ約２０ｃｍの披針形、全緑で、やや鎌形に曲がり、柄があり互生する。
[Eucalyptus leaf extract]
Eucalyptus used in the present invention is a plant belonging to the genus Eucalyptus, and the scientific name is called Eucalyptus globulus. It is distributed in the southeastern end of Australia and Tasmania Island, and is used for afforestation in various parts of the world due to its cold resistance and fast growth. Many were planted on the Mediterranean coast, and were planted in Japan at the beginning of the Meiji era. It is an evergreen tree with a tree height of 45 to 55 m and a diameter of 1.2 to 2 m. The bark is gray and flakes are stripped, leaving a blue-gray bald mark. The leaves are markedly atypical, wakagi are about 10 cm long oval and unpatterned, and mature trees are about 20 cm long needle-shaped, all green, slightly green sickle-shaped, and have a pattern and are reciprocal.
本発明に用いられるユーカリ葉抽出物は、ユーカリの葉を、そのままもしくは乾燥させた後、各種溶媒にて抽出したものであり、抽出液そのもの、もしくはその濃縮物をいう。抽出に用いられる溶媒としては、炭化水素、エステル、ケトン、エーテル、ハロゲン化炭化水素、水溶性のアルコール類及び水などが挙げられる。中でも好ましくは水、低級アルコール、多価アルコールの１種または２種以上を用いて得られる抽出物であり、更に好ましくは水、エタノール、１，３−ブチレングリコールの１種または２種以上を用いて得られる抽出物である。抽出方法は、ユーカリの葉に抽出溶媒を加えて１時間以上浸漬し、ろ過することで抽出液を得ることができる。得られた抽出液は、そのまま用いてもよく、あるいは溶媒留去により濃縮したり、カラムクロマトグラフィーや溶媒分画等の処理により精製したりしてもよい。 The eucalyptus leaf extract used in the present invention is obtained by extracting eucalyptus leaves as they are or after drying with various solvents, and refers to the extract itself or a concentrate thereof. Examples of the solvent used for extraction include hydrocarbons, esters, ketones, ethers, halogenated hydrocarbons, water-soluble alcohols and water. Among them, preferred is an extract obtained by using one or more of water, lower alcohol and polyhydric alcohol, and more preferred is one or more of water, ethanol and 1,3-butylene glycol. It is an extract obtained. In the extraction method, an extraction solvent can be added to eucalyptus leaves, immersed for 1 hour or longer, and filtered to obtain an extract. The obtained extract may be used as it is, or may be concentrated by distilling off the solvent, or may be purified by treatment such as column chromatography or solvent fractionation.
〔ウコン根茎抽出物〕
本発明に用いられるウコンは、ショウガ科ウコン属に属する植物であり、学名はCurcuma longaと呼ばれている。香辛料や染料に利用される多年草であり、高温多湿を好み、インドから東南アジアを中心として熱帯や亜熱帯で広く栽培され、日本でも、沖縄等の西南日本の暖かいところで栽培されている。根茎は太くショウガ状で、直径３〜４ｃｍとなり、表面には輪状に節があり、肉質は鮮褐色である。
[Turmeric rhizome extract]
Turmeric used in the present invention is a plant belonging to the genus Turmeric belonging to the ginger family, and its scientific name is called Curcuma longa. It is a perennial plant used for spices and dyes, likes high temperature and high humidity, is widely cultivated in India and Southeast Asia, and in the tropical and subtropical regions. In Japan, it is also cultivated in warm Southwestern Japan such as Okinawa. The rhizome is thick and ginger-shaped, has a diameter of 3 to 4 cm, has a ring-shaped node on the surface, and the flesh is bright brown.
本発明に用いられるウコン根茎抽出物は、ウコンの根茎を、そのままもしくは乾燥させた後、各種溶媒にて抽出したものであり、抽出液そのもの、もしくはその濃縮物をいう。抽出に用いられる溶媒としては、炭化水素、エステル、ケトン、エーテル、ハロゲン化炭化水素、水溶性のアルコール類及び水などがあげられる。中でも好ましくは水、低級アルコール、多価アルコールの１種または２種以上を用いて得られる抽出物であり、更に好ましくは水、エタノール、１，３−ブチレングリコールの１種または２種以上を用いて得られる抽出物である。抽出方法は、ウコンの根茎をそのままもしくはスライスしてから乾燥させたものに、抽出溶媒を加えて１時間以上浸漬し、ろ過することで抽出液を得ることができる。得られた抽出液は、そのまま用いてもよく、あるいは溶媒留去により濃縮したり、カラムクロマトグラフィーや溶媒分画等の処理により精製したりしてもよい。 The turmeric rhizome extract used in the present invention is obtained by extracting turmeric rhizomes as they are or after drying them with various solvents, and refers to the extract itself or its concentrate. Examples of the solvent used for extraction include hydrocarbons, esters, ketones, ethers, halogenated hydrocarbons, water-soluble alcohols and water. Among them, preferred is an extract obtained by using one or more of water, lower alcohol and polyhydric alcohol, and more preferred is one or more of water, ethanol and 1,3-butylene glycol. It is an extract obtained. The extraction method can obtain an extract by adding an extraction solvent to a dried turmeric rhizome as it is or after slicing and immersing for 1 hour or longer and filtering. The obtained extract may be used as it is, or may be concentrated by distilling off the solvent, or may be purified by treatment such as column chromatography or solvent fractionation.
〔エストロゲン様作用剤〕
本発明のエストロゲン様作用剤は、上記のユーカリ葉抽出物、あるいはユーカリ葉抽出物とウコン根茎抽出物からなるものであり、医薬品、医薬部外品、化粧品類（例えば、化粧水、乳液、クリーム、ジェル、美容液、パック、オイル、軟膏、スプレー、貼付剤など）として利用することができる。本発明のエストロゲン作用剤を医薬として適用する場合は、各種疾患又は症状を治療又は改善する目的、例えば、エストラジオールの欠乏による障害, 乳汁分泌の阻止や停止, ***抑制, 乳癌や前立腺癌の回復を目的として用いることができる。
[Estrogen-like agent]
The estrogenic agent of the present invention comprises the above-mentioned eucalyptus leaf extract, or eucalyptus leaf extract and turmeric rhizome extract, and is used for pharmaceuticals, quasi drugs, cosmetics (for example, lotion, milky lotion, cream , Gels, serums, packs, oils, ointments, sprays, patches, etc.). When the estrogen agonist of the present invention is applied as a pharmaceutical, for the purpose of treating or ameliorating various diseases or symptoms, such as disorders caused by deficiency of estradiol, prevention or termination of lactation, suppression of ovulation, recovery of breast cancer or prostate cancer It can be used as a purpose.
〔皮膚外用剤〕
本発明の皮膚外用剤は、上記のユーカリ葉抽出物、あるいはユーカリ葉抽出物とウコン根茎抽出物を含有するものであり、通常、ユーカリ葉抽出物のみを０．０００１〜５質量％、あるいはユーカリ葉抽出物を０．０００１〜５質量％とウコン根茎抽出物を０．０００１〜５質量％含有するものである。本発明における抽出物の質量は、実際に溶媒を除去して乾燥させた残留物の質量のみならず、残留物に含まれる溶媒量を算出し、その溶媒量を減じた残留物の質量も概念的に包含される。例えば、抽出溶媒が揮発性である場合は、抽出溶媒を１０５℃〜１２０℃で完全に留去させ、残存した固形分の質量であり、抽出溶媒が不揮発性である場合は、高速液体クロマトグラフィー等で溶媒量を定量し、それ以外の成分量が抽出物の質量である。
[Skin external preparation]
The topical skin preparation of the present invention contains the above-mentioned eucalyptus leaf extract or eucalyptus leaf extract and turmeric rhizome extract, and usually only 0.0001 to 5% by mass of eucalyptus leaf extract or eucalyptus It contains 0.0001-5% by mass of leaf extract and 0.0001-5% by mass of turmeric rhizome extract. The mass of the extract in the present invention is not only the mass of the residue actually removed by removing the solvent but also the mass of the residue obtained by calculating the amount of the solvent contained in the residue and subtracting the amount of the solvent. Is included. For example, when the extraction solvent is volatile, the extraction solvent is completely distilled off at 105 ° C. to 120 ° C., and is the mass of the remaining solid content. When the extraction solvent is nonvolatile, high performance liquid chromatography The amount of the solvent is quantified by, for example, and the amount of other components is the mass of the extract.
ユーカリ葉抽出物およびウコン根茎抽出物の配合量は、上記のとおり、通常、それぞれ０．０００１〜５質量％であり、好ましくはそれぞれ０．００１〜１質量％である。それぞれの配合量が０．０００１％未満では肌荒れ改善効果、シワ防止・改善効果、美肌効果を発揮させることが困難となることがあり、５％質量を超えると製剤の安定性に問題が生じ易くなることがあり好ましくない。 The amount of the eucalyptus leaf extract and the turmeric rhizome extract is usually 0.0001 to 5% by mass, preferably 0.001 to 1% by mass, respectively, as described above. If the blending amount is less than 0.0001%, it may be difficult to exert a rough skin improvement effect, wrinkle prevention / improvement effect, and beautifying skin effect. If it exceeds 5% mass, a problem may occur in the stability of the preparation. This is not preferable.
本発明の皮膚外用剤は、様々な剤形にて調製することができ、例えば、化粧水、乳液、クリーム、ジェル、美容液、パック、オイル、軟膏、スプレー、貼付剤などとして利用することができる。本発明の皮膚外用剤においては、化粧料や医薬品等の皮膚外用剤に常用されている添加物を、本発明の効果を損なわない範囲で、適宜配合することが可能である。 The external preparation for skin of the present invention can be prepared in various dosage forms. For example, it can be used as a lotion, milky lotion, cream, gel, cosmetic liquid, pack, oil, ointment, spray, patch, etc. it can. In the external preparation for skin of the present invention, additives commonly used in external preparations for skin such as cosmetics and pharmaceuticals can be appropriately blended within a range not impairing the effects of the present invention.
以下、実施例および比較例を挙げて本発明をさらに具体的に説明する。なお、特に断りのない限り、％は質量％を表わす。 Hereinafter, the present invention will be described more specifically with reference to examples and comparative examples. Unless otherwise specified,% represents mass%.
〔ユーカリ葉抽出物の調製〕
乾燥したユーカリの葉１００ｇに１０００ｇの５０％エタノール水溶液を加えて室温で１週間抽出し、ろ過することによりユーカリ葉の抽出液を得た。この抽出液をロータリーエバポレーターで減圧下、６０℃で乾燥濃縮し、ユーカリ葉抽出物２２．８ｇを得た。
[Preparation of eucalyptus leaf extract]
To 100 g of dried eucalyptus leaves, 1000 g of 50% ethanol aqueous solution was added and extracted at room temperature for 1 week, followed by filtration to obtain an extract of eucalyptus leaves. This extract was dried and concentrated at 60 ° C. under reduced pressure using a rotary evaporator to obtain 22.8 g of a eucalyptus leaf extract.
〔ウコン根茎抽出物の調製〕
ウコンの根茎をスライスし乾燥させたもの１００ｇに１０００ｇの５０％エタノール水溶液を加えて室温で１週間抽出し、ろ過することによりウコン根茎の抽出液を得た。この抽出液をロータリーエバポレーターで減圧下、６０℃で乾燥濃縮し、ユーカリ葉抽出物１２．０ｇを得た。
(Preparation of turmeric rhizome extract)
A turmeric rhizome extract was obtained by adding 1000 g of 50% ethanol aqueous solution to 100 g of sliced and dried turmeric rhizome, followed by extraction at room temperature for 1 week, and filtration. The extract was dried and concentrated at 60 ° C. under reduced pressure using a rotary evaporator to obtain 12.0 g of a eucalyptus leaf extract.
〔実施例１，２、比較例１：エストロゲン様作用活性の測定〕
上記のユーカリ葉抽出物およびウコン根茎抽出物を用いて、下記の方法によりエストロゲン様作用活性を測定した。なお、エストロゲン様作用活性の測定には、ユーカリ葉抽出物単独（実施例１）、ウコン根茎抽出物単独（比較例１）、およびそれら両成分の等量混合物（実施例２）を試料とした。その結果を表１に示す。
[Examples 1 and 2, Comparative Example 1: Measurement of estrogenic activity]
Using the above-mentioned eucalyptus leaf extract and turmeric rhizome extract, estrogenic activity was measured by the following method. For the measurement of estrogenic activity, eucalyptus leaf extract alone (Example 1), turmeric rhizome extract alone (Comparative Example 1), and an equal mixture of both components (Example 2) were used as samples. . The results are shown in Table 1.
〔エストロゲン様作用活性の測定〕
エストロゲン様作用活性を、エストロゲン依存性細胞の増殖に対する影響を調べる方法（Invitrocell. Dev. Biol. 28A, 595-602, 1992）で、測定した。すなわち、ヒト乳がん細胞由来ＭＣＦ−７細胞（理研細胞バンク、ＪＣＲＢ０１３４）を５％ＦＢＳ（チャコール・デキストラン処理）、１ｍＭピルビン酸ナトリウムを含有するEagle's MEM （フェノールレッド除去）を用いて、２．５×１０4個／ｍＬの細胞密度で浮遊させた細胞懸濁培地０．２ｍＬを９６穴培養プレートに播種し、２４時間培養後、各試料を表１に記載の設定濃度になるように培地で調整した試料溶液２０μＬを９６穴培養プレートに添加した。６日間培養後、ＭＴＴ還元法にて生細胞数の測定を行った。エストロゲン様作用活性は、試料無添加で培養した生細胞数に対する試料添加で培養した生細胞数の割合（相対値％）で表わした。
[Measurement of estrogenic activity]
The estrogenic activity was measured by a method (Invitrocell. Dev. Biol. 28A, 595-602, 1992) for examining the effect on the proliferation of estrogen-dependent cells. That is, human breast cancer cell-derived MCF-7 cells (RIKEN Cell Bank, JCRB0134) were treated with 2.5% FBS (charcoal dextran treatment) and Eagle's MEM (phenol red removed) containing 1 mM sodium pyruvate. Cell suspension medium (0.2 mL) suspended at a cell density of 10 4 cells / mL is seeded in a 96-well culture plate, cultured for 24 hours, and each sample is adjusted with the medium to the set concentration shown in Table 1. 20 μL of the prepared sample solution was added to a 96-well culture plate. After culturing for 6 days, the number of viable cells was measured by MTT reduction method. The estrogenic activity was expressed as a ratio (relative value%) of the number of living cells cultured with the addition of the sample to the number of living cells cultured without the addition of the sample.
表１の結果から、ユーカリ葉抽出物のみを用いた実施例１では、ウコン根茎抽出物単独（比較例１）に比べて、濃度依存的に高いエストロゲン様作用活性が認められた。さらに、ユーカリ葉抽出物とウコン根茎抽出物を組み合わせた試料（実施例２）では、両抽出物の総濃度と同じ濃度のユーカリ葉抽出物単独（実施例１）やウコン根茎抽出物単独（比較例１）に比べて、どの濃度においても飛躍的にエストロゲン様作用活性が増加していることが分かる。したがって、両抽出物を組み合わせることによる相乗効果が認められた。 From the results of Table 1, in Example 1 using only the eucalyptus leaf extract, higher estrogen-like activity was observed in a concentration-dependent manner than the turmeric rhizome extract alone (Comparative Example 1). Furthermore, in the sample combining eucalyptus leaf extract and turmeric rhizome extract (Example 2), eucalyptus leaf extract alone (Example 1) having the same concentration as the total concentration of both extracts or turmeric rhizome extract alone (comparison) Compared to Example 1), it can be seen that the estrogenic activity increased dramatically at any concentration. Therefore, the synergistic effect by combining both extracts was recognized.
〔皮膚外用剤の評価〕
上記のユーカリ葉抽出物およびウコン根茎抽出物を使用し、表２に示す化粧水（皮膚外用剤）を調製し、下記の６項目の評価項目について評価を行った。その結果を表２に示す。
[Evaluation of external preparation for skin]
Using the above-mentioned eucalyptus leaf extract and turmeric rhizome extract, skin lotions (external preparations for skin) shown in Table 2 were prepared, and the following 6 evaluation items were evaluated. The results are shown in Table 2.
（評価項目及び評価基準）
（１）肌荒れ改善効果
肌荒れを生じている１０名の女性（３２才〜５０才）をパネラーとし、皮膚外用剤を一日２回ずつ連日２週間に渡って使用した時の肌の状態について官能検査し、下記のように判定し、１０名の平均値を求めて、平均値１．５点以上を肌荒れ改善効果のある皮膚外用剤であると評価した。
２点：肌荒れが明らかに治ってきたと感じた場合。
１点：肌荒れがやや治ってきたと感じた場合。
０点：肌荒れ改善効果が全く見られないと感じた場合。
(Evaluation items and evaluation criteria)
(1) Rough skin improvement effect 10 females (32 to 50 years old) who have rough skin are used as panelists, and the skin condition when using a topical skin preparation twice a day for two consecutive days is sensory. It examined and determined as follows, calculated | required the average value of 10 persons, and evaluated the average value 1.5 point or more as a skin external preparation with a rough skin improvement effect.
2 points: When it is felt that rough skin has been cured.
1 point: When it feels that the rough skin has been cured somewhat.
0 point: When it feels that the rough skin improvement effect is not seen at all.
（２）シワ防止・改善効果
２０名の女性（２８才〜６１才）をパネラーとし、皮膚外用剤を一日２回ずつ連日４週間に渡って使用した時の肌の状態について官能検査し、下記のように判定し、２０名の平均値を求めて、平均値１．５点以上をシワ防止・改善効果のある皮膚外用剤であると評価した。
２点：シワが明らかに少なくなったと感じた場合。
１点：シワがやや少なくなってきたと感じた場合。
０点：シワが減少しない、もしくは増えたと感じた場合。
(2) Wrinkle prevention / improvement effect 20 females (28 to 61 years old) are panelists, and the skin condition when using a skin external preparation twice a day for 4 consecutive days is subjected to a sensory test. The average value of 20 persons was determined as follows, and an average value of 1.5 points or more was evaluated as a skin external preparation having an effect of preventing wrinkles and improving it.
2 points: When wrinkles are clearly reduced.
1 point: When wrinkles are felt to be slightly reduced.
0 points: When wrinkles are not reduced or increased.
（３）美肌効果
２０名の女性（２８才〜６１才）をパネラーとし、皮膚外用剤を一日２回ずつ連日２週間に渡って使用した時の肌の状態について官能検査し、下記のように判定し、２０名の平均値を求めて、平均値１．５点以上を肌にはりと透明感を与える効果のある皮膚外用剤であると評価した。
２点：明らかに肌にはりがでて、若々しくなったと感じた場合。
１点：やや肌にはりがでて、肌がやや若々しくなったと感じた場合。
０点：肌のはりに変化がなく、美肌効果が弱いと感じた場合。
(3) Skin beautification 20 females (28 to 61 years old) are panelists, and the skin condition when skin external preparations are used twice a day for two consecutive days, is as follows. The average value of 20 persons was determined, and an average value of 1.5 points or more was evaluated as a skin external preparation having an effect of giving a skin feel and transparency.
2 points: When you feel that your skin is obviously bruised and youthful.
1 point: When the skin feels somewhat skinny and the skin feels a little youthful.
0 point: When there is no change in the skin tone and the skin beautifying effect is weak.
（４）肌へのなじみ性
２０名の女性（２８才〜６１才）をパネラーとし、洗顔した後に皮膚外用剤を使用した時の感触について下記のように判定し、２０名の平均値を求めて、平均値１．５点以上を使用時の感触の良好な皮膚外用剤であると評価した。
２点：使用時に肌へのなじみが良いと感じた場合。
１点：使用時に肌へのなじみがやや悪いと感じた場合。
０点：使用時に肌へのなじみが明らかに悪いと感じた場合。
(4) Familiarity to the skin 20 panelists (28 to 61 years old) are panelists, and the skin feel is determined as follows after washing the face, and the average of 20 persons is obtained. An average value of 1.5 points or more was evaluated as a skin external preparation having a good feel during use.
2 points: When you feel familiar with the skin during use.
1 point: When the user feels that the familiarity with the skin is slightly bad.
0 points: When the user feels that the familiarity with the skin is clearly bad.
（５）使用後のべたつき
２０名の女性（２８才〜６１才）をパネラーとし、洗顔した後に皮膚外用剤を使用して１０分後の肌の感触について下記のように判定し、２０名の平均値を求めて、平均値１．５点以上を使用後のべたつきがない皮膚外用剤であると評価した。
２点：べたつきが無いと感じた場合。
１点：肌がややべたつくと感じた場合。
０点：肌が非常にべたつくと感じた場合。
(5) Stickiness after use 20 women (28 to 61 years old) are panelists, and after washing their face, using a topical skin preparation, the skin feel after 10 minutes is determined as follows. An average value was obtained, and an average value of 1.5 points or more was evaluated as a skin external preparation having no stickiness after use.
2 points: When there is no stickiness.
1 point: When the skin feels somewhat sticky.
0 points: When the skin feels very sticky.
（６）経時安定性
化粧水を透明ガラス容器に密封して０℃、２５℃、４０℃で３ヶ月間保存し、その外観を観察して、下に示す３段階で評価した。
○：安定性良好（いずれの温度においても外観の変化がない。）
△：安定性やや不良（いずれかの温度において若干の澱（おり）、沈殿を生じるまたは若干変色を生じる。）
×：安定性不良（いずれかの温度において澱（おり）、沈殿を生じるまたは分離する。もしくは変色が著しい。）
(6) Stability over time The skin lotion was sealed in a transparent glass container and stored at 0 ° C., 25 ° C., and 40 ° C. for 3 months. The appearance was observed and evaluated in the following three stages.
○: Good stability (no change in appearance at any temperature)
Δ: Slightly poor (slight stagnation, precipitation or slight discoloration at any temperature)
X: poor stability (starch (cured), precipitate is formed or separated at any temperature, or discoloration is remarkable)
実施例３，４と比較例２，３の対比より、ユーカリ葉抽出物あるいはユーカリ葉抽出物とウコン根茎抽出物を組み合わせた本発明に係る化粧水は、比較例２，３のものよりも肌荒れ改善効果、シワ防止・改善効果、美肌効果に優れていることが分かる。また、実施例３，４の化粧水は、両抽出物を含有しない比較例３と、肌へのなじみ性や使用後のべたつき等の使用感、経時安定性が同等であることから、ユーカリ葉抽出物やウコン根茎抽出物がこれらの性能を損なわないことも分かる。すなわち、本発明に係る化粧水が、肌荒れ改善効果、シワ防止・改善効果、美肌効果に優れ、かつ肌へのなじみが良く、使用後のべたつきが無い等の使用感にも優れるとともに、経時安定性にも優れることが分かる。 From the comparison between Examples 3 and 4 and Comparative Examples 2 and 3, the skin lotion according to the present invention in which the eucalyptus leaf extract or the eucalyptus leaf extract and the turmeric rhizome extract are combined is rougher than that of Comparative Examples 2 and 3. It turns out that it is excellent in the improvement effect, the wrinkle prevention / improvement effect, and the skin beautifying effect. Further, the skin lotions of Examples 3 and 4 are similar to Comparative Example 3 that does not contain both extracts, and the skin feel and the feeling of use such as stickiness after use and the stability over time are equivalent. It can also be seen that the extract and turmeric rhizome extract do not impair these performances. That is, the skin lotion according to the present invention is excellent in rough skin improvement effect, wrinkle prevention / improvement effect, beautifying skin effect, is well-familiar to the skin, has excellent feeling of use such as no stickiness after use, and is stable over time. It turns out that it is excellent also in property.
一方、比較例２、３では、十分な性能が得られていなかった。つまり、ウコン根茎抽出を単独に配合した比較例２の化粧水では、肌荒れ改善効果、シワ防止・改善効果、美肌効果が実施例３，４よりも弱くなっており、さらにユーカリ葉抽出物とウコン根茎抽出物の両成分とも配合していない比較例３の化粧水では、それらの効果がより弱くなっていることが分かる。 On the other hand, in Comparative Examples 2 and 3, sufficient performance was not obtained. That is, in the lotion of Comparative Example 2 containing turmeric rhizome extract alone, the skin roughening effect, wrinkle prevention / improvement effect, and skin beautifying effect are weaker than those of Examples 3 and 4, and further, Eucalyptus leaf extract and turmeric It turns out that those effects are weaker in the lotion of the comparative example 3 which is not mix | blending both components of the rhizome extract.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010281748A JP5724359B2 (en) | 2010-12-17 | 2010-12-17 | Estrogen-like agent and topical skin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010281748A JP5724359B2 (en) | 2010-12-17 | 2010-12-17 | Estrogen-like agent and topical skin preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012126695A true JP2012126695A (en) | 2012-07-05 |
| JP5724359B2 JP5724359B2 (en) | 2015-05-27 |
Family
ID=46644142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010281748A Active JP5724359B2 (en) | 2010-12-17 | 2010-12-17 | Estrogen-like agent and topical skin preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5724359B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101877047B1 (en) * | 2016-04-22 | 2018-07-10 | (주)에스디생명공학 | Composition for preventing or improving skin wrinkle comprising Eucalyptus globulus extract treated by enzyme as active ingredient |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000169359A (en) * | 1998-09-30 | 2000-06-20 | Kao Corp | Ceramide production promoter |
| JP2001039823A (en) * | 1999-07-30 | 2001-02-13 | Ichimaru Pharcos Co Ltd | Cosmetic composition containing humectant plant extract |
| JP2002205950A (en) * | 2001-01-10 | 2002-07-23 | Ichimaru Pharcos Co Ltd | Elastase activity inhibitor and cosmetic composition |
| JP2005298487A (en) * | 2004-03-16 | 2005-10-27 | Shiseido Co Ltd | Perfume composition for controlling regulating function of female hormone |
| JP2009108050A (en) * | 2008-10-10 | 2009-05-21 | Tsujido Kagaku Kk | Therapeutic agent |
| JP2009155227A (en) * | 2007-12-25 | 2009-07-16 | Yohei Tanaka | Living body tissue repair promoting drug |
| JP2010116348A (en) * | 2008-11-13 | 2010-05-27 | Maruzen Pharmaceut Co Ltd | Antiinflammatory agent, antiaging agent and skin external preparation |
-
2010
- 2010-12-17 JP JP2010281748A patent/JP5724359B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000169359A (en) * | 1998-09-30 | 2000-06-20 | Kao Corp | Ceramide production promoter |
| JP2001039823A (en) * | 1999-07-30 | 2001-02-13 | Ichimaru Pharcos Co Ltd | Cosmetic composition containing humectant plant extract |
| JP2002205950A (en) * | 2001-01-10 | 2002-07-23 | Ichimaru Pharcos Co Ltd | Elastase activity inhibitor and cosmetic composition |
| JP2005298487A (en) * | 2004-03-16 | 2005-10-27 | Shiseido Co Ltd | Perfume composition for controlling regulating function of female hormone |
| JP2009155227A (en) * | 2007-12-25 | 2009-07-16 | Yohei Tanaka | Living body tissue repair promoting drug |
| JP2009108050A (en) * | 2008-10-10 | 2009-05-21 | Tsujido Kagaku Kk | Therapeutic agent |
| JP2010116348A (en) * | 2008-11-13 | 2010-05-27 | Maruzen Pharmaceut Co Ltd | Antiinflammatory agent, antiaging agent and skin external preparation |
Non-Patent Citations (2)
| Title |
|---|
| CELLUL COMMUN., VOL.11 NO.1 P.22-25 (2004), JPN6014048035, ISSN: 0002939235 * |
| 皮膚, VOL.42 NO.2 P.264-269 (2000), JPN6014048038, ISSN: 0002939236 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101877047B1 (en) * | 2016-04-22 | 2018-07-10 | (주)에스디생명공학 | Composition for preventing or improving skin wrinkle comprising Eucalyptus globulus extract treated by enzyme as active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5724359B2 (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016307932B2 (en) | Compositions including Ampelopsis grossedentata and Albizia julibrissin extracts and methods of use | |
| CN106727149A (en) | A kind of gentle makeup remover of compacting | |
| US20130251827A1 (en) | Cosmetic composition for skin moisturisation comprising pine-resin extract, pinus densiflora needle extract and pinus densiflora root extract | |
| KR20160120355A (en) | Skin-brightening cosmetic composition | |
| CN108066244A (en) | A kind of composition containing brown algae polyphenols | |
| JP5736737B2 (en) | Epidermal keratinocyte activator | |
| JP5724359B2 (en) | Estrogen-like agent and topical skin preparation | |
| JP2012020950A (en) | Inhibitor of endothelin action and whitening agent | |
| KR101690012B1 (en) | Composition for Treating Dermatitis Comprising Extract of Weeping Fern | |
| AU2018359924B2 (en) | Composition for eliminating striae distensae | |
| JP2012092069A (en) | Estrogen-like active agent and skin external preparation | |
| KR20100037508A (en) | Cosmetic composite of containing hemerocallis fulva extract lived in the jirisan | |
| CN110946777A (en) | Allantoin nano emulsion for feet and preparation method thereof | |
| JP6265025B2 (en) | Estrogenic agent | |
| EP2866787A2 (en) | Essential oil of sweet marjoram, composition comprising it, cosmetic treatment method and use | |
| KR101917252B1 (en) | Composition for external application comprising protopanaxadiol group compound | |
| TW201414504A (en) | Inhibiting melanogenesis with essential oils extracted from Vitex negundo Linn leaves | |
| EP4144345A1 (en) | Prunella vulgaris extract and use thereof | |
| KR101682458B1 (en) | Cosmetic composition for slimming | |
| JP7274720B2 (en) | Estrogen receptor expression promoter and cell proliferation promoter | |
| JP6807425B2 (en) | Endo180 production promoter | |
| US20210177727A1 (en) | Extracts of plants containing polygodial, compositions comprising such extracts and cosmetic and/or dermatological uses thereof | |
| KR102585725B1 (en) | Composition for improving skin condition comprising herb extracts mixture | |
| Shah et al. | POLY HERBAL SKIN CLARIFYING AND UV PROTECTION CREAM | |
| CN111743843A (en) | Methods and compositions for treating seasonal changes in skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150113 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150303 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150316 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5724359 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |